PMN
ProMIS Neurosciences Inc.Company with tickers: PMN
CIK
1374339
CUSIP
74346M505
Shares Outstanding
8,967,693
Investor Relations
https://www.promisneurosciences.com/investors
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | — | ||||
| Revenue (ASC 606) | — | ||||
| Cost of Revenue | — | ||||
| Gross Profit | — | ||||
| Operating Expenses | $8,644,895 | USD | 2026-03-31 | 10-Q | 2026-05-12 |
| Research & Development | $6,971,005 | USD | 2026-03-31 | 10-Q | 2026-05-12 |
| Operating Income | $-8,644,895 | USD | 2026-03-31 | 10-Q | 2026-05-12 |
| Net Income | $-8,244,372 | USD | 2026-03-31 | 10-Q | 2026-05-12 |
| EPS (Basic) | $-1.26 | USD/shares | 2026-03-31 | 10-Q | 2026-05-12 |
| EPS (Diluted) | $-1.26 | USD/shares | 2026-03-31 | 10-Q | 2026-05-12 |